Can Emcure’s Cut-Price Eribulin Dull Halaven In India?
Emcure has launched a generic version of Eisai’s cancer drug Halaven on the Indian market at a sharp 40% discount to the innovator product, and hopes to expand patient access significantly.
You may also be interested in...
Emcure's Hinjwadi, India, plant should have investigated other more likely sources of contamination more thoroughly, the FDA says.
Indian drug company Emcure says it is launching the first generic version of Japanese drugmaker Eisai's Halaven which targets metastatic breast cancer and will undercut the branded drug’s price in the country by nearly half.
Japan's Eisai appears set for a significant step up in product introductions in India. Improving access to these medicines for patients in the largely self-pay market is at the fulcrum of its strategy, Dr Sanjit Singh Lamba, managing director of Eisai Pharmaceuticals India Pvt Ltd, tells Scrip. Newer options like a second brand approach may also be evaluated for certain new products to expand access and availability across the country.